Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a sticky patch on your chest predict heart failure relapse?

NCT ID NCT07699874

Knowledge-focused Sponsor: University of Monastir Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This pilot study investigates whether a continuous remote ECG monitor, worn as a chest patch, can predict hospital readmission or death within 30 days after discharge in patients with heart failure and atrial fibrillation. Fifty participants will wear the Vivalink ECG patch at home, which streams real-time heart data to healthcare providers. The goal is to see if early warning signs can be detected before a patient's condition worsens, potentially improving follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vivalink multi-vital wearable ECG monitor (chest-worn biosensor patch)
What this could lead to
If successful, this approach could help doctors identify patients at high risk of readmission early, potentially reducing hospital returns and improving care after discharge.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to all patients. The device may be uncomfortable or fail to detect all relevant events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with HF decompensation who will be discharged from the emergency department of Fattouma Bourguiba University Hospital (Monastir, Tunisia) and emergency department of Sahloul University Hospital following HF decompensation.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (1) Patients having an HF decompensation diagnosis, patients with reduced ejection fraction\<50%, (2) having a documented AF (3) have a plan for discharging with partnering home health services, (4) agree to use the wearable ECG patch for 30 days (5) with a permanent residential address (6) without significant cognitive impairment and (7) understand English language. \- Exclusion Criteria: (1) patients having implanted pacemaker or any electrical devices; (2) having an allergy to hydrocolloid gel adhesive or skin diseases; (3) unstable vital signs, (4) being on dialysis; (5) having a documented visual, cognitive, or physical impairment that would interfere with the ability to comply with the study procedures, (6) pregnant women (7) having inability to give an informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure, acute Telemonitoring

Contacts and locations

Locations

  • Fattouma Bourguiba University Hospital

    Monastir, 5000, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.